nanotech investing Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
nanotech investing Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
nanotech investing Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
nanotech investing Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
nanotech investing Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
nanotech investing Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
nanotech investing Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
nanotech investing Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
